Example: bachelor of science
N-Nitrosodimethylamine (NDMA) - World Health …
There is also ample evidence that NDMA is genotoxic both in vivo and in vitro. Activation by liver microsomal S9 fractions is necessary for a positive in vitro result. The recent observation that human S9 fractions are much more active in promoting genotoxicity in the Ames test than rat S9 fractions suggests that humans may be especially ...
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
ICH guideline M7 on assessment and control of DNA reactive ...
www.ema.europa.euNo. The terms “mutagenic potential” and “genotoxic potential” are not interchangeable. Mutagenic potential refers to the ability of a compound to induce point mutations (i.e., bacterial reverse mutation assay), while genotoxic potential refers to both mutagenic and clastogenic potential. ICH M7 focuses specifically on
A C DNA R (M P L P C R M7(R1) - ICH
database.ich.orgsome cases where a drug substance intended for other indications is itself genotoxic at therapeutic concentrations and may be expected to be associated with an increased cancer risk. Exposure to a mutagenic impurity in these cases would not significantly add to the
Table of Genetic Disorders - Loyola University Chicago
www.meddean.luc.eduenvironmental genotoxic agents. Title: Microsoft Word - Table of Genetic Disorders.doc Author: afrankf Created Date: 4/21/2005 9:59:39 PM ...
Genotoxic Impurities and Its Risk Assessment in Drug …
lupinepublishers.comGenotoxic impurities can get incorporated into drug substances through the various sources, the major source is the starting material used in the synthesis of drug substances and its impurities. Similarly, genotoxic intermediate and by-products formed in the synthesis process may get be carried forward to the drug substances as genotoxic ...